Loading data for IONS — first visit, this takes a few seconds.

알림

Ionis Pharmaceuticals Inc... (IONS)

NasdaqGS: IONS · 실시간 가격 · USD

61.10

+1.48 (2.48%)

종가 기준: Aug 19, 2026, 7:02 PM

2.48% (1D)

데이터 없음

매수호가	n/a
시가총액	10.15B
매출 (ttm)	874.09M
순이익 (ttm)	-565.17M
베타	0.40
EPS (ttm)	-3.48
P/E (ttm)	n/a
선행 P/E	-57.94
P/B (ttm)	23.01
P/S (ttm)	11.62
Earnings Date	Nov 4, 2026

매도호가	n/a
거래량	1,698,695
평균 거래량 (20일)	2,880,609
시가	60.20
전일 종가	59.62
일중 범위	59.61 - 61.19
52주 범위	41.71 - 86.74
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IONS 소개

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) i...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 May 17, 1991

직원 수 1,480

상장 거래소 NasdaqGS

티커 IONS

웹사이트 https://www.ionis.com

전체 기업 정보

재무 실적

2025년 Ionis Pharmaceuticals의 매출은 943.71M로, 전년 705.14M 대비 33.83% 증가했습니다. 순이익은 -381.39M로, -15.97% 감소했습니다.

재무제표

어닝 서프라이즈

Ionis Pharmaceuticals가 Jul 29, 2026에 분기 실적을 발표했습니다:

매출 $267.95M 예상치 하회 $0, 및 -40.73% 전년 대비 감소.

EPS -0.42 예상치 상회 0.46, 및 -149.41% 전년 대비 감소.

다음 실적 발표

Ionis Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 4, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3일 전 · Simply Wall St.

Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain?

Ionis Pharmaceuticals (IONS) has drawn investor attention after recent share price moves, with the stock up over the past month but down over the past 3 months. That mixed pattern sets the stage for a...

5일 전 · Motley Fool

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

A drug that didn't meet expectations in a trial is to blame.

1주 전 · Motley Fool

Ionis (IONS) Q2 2026 Earnings Call Transcript

Revenue hit $268 million with 56% growth, while TRYNGOLZA sales accelerated.

2주 전 · Motley Fool

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement.

2주 전 · Trefis

Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?

The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.

2 페이지 중 1

Ionis Pharmaceuticals Inc... (IONS)